Back to search
FDAFDA · Food and drugs·Recall number D-0804-2018

Docetaxel injection concentrate, 20 mg/mL, 1 mL vial, Rx only, Winthrop U.S. a business of Sanofi-Aventis U.S. LLC., NDC 0955-1020-01

Published May 9, 2018 · Recall initiated: April 27, 2018

Summary

FDA records drug Class II recall D-0804-2018, published May 9, 2018 and initiated April 27, 2018. Recalling firm: Sanofi-Aventis U.S. LLC; Status: Terminated; Reported quantity: 19580 vials; Lot: Lot #: 7F307A, 7F307C, Exp 01/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent drug: over-concentrated vials of Docetaxel injection concentrate 20 mg/mL may have been distributed.

What to do

Voluntary: Firm initiated · Letter

Get an email if DOCETAXEL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DOCETAXEL
Manufacturer
Sanofi-Aventis U.S. LLC
Distributor
US nationwide
Lot
Lot #: 7F307A, 7F307C, Exp 01/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Docetaxel injection concentrate, 20 mg/mL, 1 mL vial, Rx only, Winthrop U.S. a business of Sanofi-Aventis U.S. LLC., NDC 0955-1020-01 recalled?

Yes. FDA published recall D-0804-2018 on May 9, 2018. Reported hazard: Superpotent drug: over-concentrated vials of Docetaxel injection concentrate 20 mg/mL may have been distributed.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DOCETAXEL.